3SBio Inc. was granted SFDA manufacturing approval of an extension of the TPIAO label to include treatment of idiopathic thrombocytopenic purpura. The approval was a long time in the making, as 3SBio originally submitted its application in December 2008. Launched in 2006, TPIAO is a recombinant human thrombopoietin product that was originally approved to treat chemotherapy-induced thrombocytopenia, or platelet deficiency. More details....

Stock Symbol: (NSDQ: SSRX)